We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Merck & Co Inc | LSE:0QAH | London | Ordinary Share | MERCK & CO ORD (CDI) |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
118.40 | 125.00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 60.12B | 365M | 0.1441 | 842.75 | 307.56B |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
19:59:46 | O | 2 | 121.4776 | USD |
Date | Time | Source | Headline |
---|---|---|---|
15/3/2024 | 15:23 | ALNC | IN BRIEF: Merck hails positive data on cervical cancer drug, Keytruda |
20/2/2024 | 21:15 | ALNC | Merck and Astellas drugs get priority review in US and Japan |
01/2/2024 | 12:57 | ALNC | TOP NEWS: Merck books 2023 growth despite gefapixant rejection hit |
19/1/2024 | 11:29 | ALNC | IN BRIEF: Arix Bioscience eyes USD19 million return from Harpoon sale |
08/1/2024 | 14:20 | ALNC | Merck to buy Harpoon Therapeutics for about USD680 million |
18/12/2023 | 11:04 | ALNC | Astellas, Merck, Pfizer celebrate US approval for Keytruda plus Padcev |
15/12/2023 | 08:41 | ALNC | Merck gets US FDA nod for Welireg, as trial with Moderna bears fruit |
11/12/2023 | 17:56 | ALNC | Merck reports mixed updates for cancer treatment, Keytruda |
26/10/2023 | 11:17 | ALNC | TOP NEWS: Merck hails Daiichi Sankyo partnership but will take charge |
20/10/2023 | 05:06 | ALNC | TOP NEWS: Daiichi Sankyo soars on USD22 billion Merck cancer drug deal |
Merck & (0QAH) Share Charts1 Year Merck & Chart |
|
1 Month Merck & Chart |
Intraday Merck & Chart |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|---|---|---|---|
08:01:35 | 121.48 | 2 | 0.00 | O |
08:01:35 | 121.36 | 1 | 0.00 | O |
08:01:15 | 121.36 | 1 | 0.00 | O |
06:01:06 | 121.39 | 230 | 0.00 | O |
06:00:35 | 121.29 | 180 | 0.00 | O |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |